HLUYY News and Press, H Lundbeck A/S S/Adr From 09/16/19

Alder BioPharmaceuticals (NASDAQ: ALDR ) announced on Monday (September 16) that it has struck a deal to be acquired by Lundbeck A/S (OTC Pink: HLUYY ) in a US$2 billion takeover. The Denmark-based company’s move to acquire Alder BioPharma puts Lundbeck in a position to potentially ...

The core business of Denmark's H. Lundbeck ( HLUYY ) (LUN.KO) is more or less an "is what it is" situation; while there is still some potential upside from the company's newer portfolio of drugs, potential market-expanding studies won't read out for years. Where the upside likely lies today ...

Danish pharmaceutical company H. Lundbeck ’s ( OTCPK:HLUYY ) (LUN.KO) first quarter is likely to be pretty much par for the course for the near term – double-digit growth from its portfolio of newer offsets that can’t offset the generic erosion of its old portfolio, with ...

Minerva Neurosciences ( NERV ) is set to report data from multiple clinical trials in 2019 but roluperidone, which NERV is developing as a treatment for the negative symptoms of schizophrenia, is likely to get a disproportionate amount of attention. NERV and others developing in the negative...

Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to...

On January 7, 2019, Axsome Therapeutics ( AXSM ) announced results from an 80-patient trial of bupropion vs AXS-05 (bupropion with dextromethorphan) in major depressive disorder ((MDD)). I recently wrote about results from the trial and the five additional upcoming catalysts for AXSM. Compar...

Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder Canada NewsWire MONTREAL, Feb. 22, 2019 MONTREAL , Feb. 22, 2019 /CNW Telbec/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Can...

Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its ...

The next few years are going to seriously challenge the skills of H. Lundbeck ’s ( OTCPK:HLUYY ) (LUN.KO) recently-hired CEO Deb Dunsire and head of R&D Johan Luthman, as the company has to contend with serious erosion in its mature portfolio, a very weak late-stage pipeline (not t...